Pemetrexed–cisplatin combination in mesothelioma

References

• Becklake MR. Asbestosis-related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am. Rev. Respir. Dis. 114, 187–227 (1976).
   PubMed Web of Science ®Google Scholar
• Boutin C, Schlesser M, Freneay C et al. Malignant pleural mesothelioma. Eur. Respir. J. 12, 972–981 (1998).
   PubMed Web of Science ®Google Scholar
• Testa JR, Pass HI, Carbone M. Molecular biology of mesothelioma. In: Cancer: Principles and Practice of Oncology. Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, PA, USA, 1937–1943 (2001).
   Google Scholar
• Bisset D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin. Oncol. (R. Coll. Radiol.) 3, 315–117 (1991).
   PubMedGoogle Scholar
• Soubra M, Dunscombe PB, Hodson DI, Wong G. Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 18, 1521–1527 (1990).
   PubMed Web of Science ®Google Scholar
• Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 111, 815–825 (1996).
   PubMed Web of Science ®Google Scholar
• Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 108, 754–758 (1995).
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Flores R, Jacklitsch M et al. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117, 54–65 (1999).
   PubMed Web of Science ®Google Scholar
• Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22, 3451–3457 (2004).
   PubMed Web of Science ®Google Scholar
• Merritt N, Blewett CJ, Miller JD. Survival after conservative management of pleural malignant mesothelioma. J. Surg. Oncol. 78, 171–174 (2001).
   PubMed Web of Science ®Google Scholar
• Ruffie P, Feld R, Minkin S. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J. Clin. Oncol. 7, 1157–1168 (1989).
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a Phase II study. J. Clin. Oncol. 17, 25–30 (1999).
   PubMed Web of Science ®Google Scholar
• Tomek S, Emri S, Krejcy K et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br. J. Cancer 88, 167–174 (2003).
   PubMed Web of Science ®Google Scholar
• Khalil MY, Mapa M, Shin HJ, Shin DM. Advances in the management of malignant mesothelioma. Curr. Oncol. Rep. 5, 334–341 (2003).
   PubMedGoogle Scholar
• Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38, 111–121 (2002).
   PubMed Web of Science ®Google Scholar
• Bischoff HG, Manegold C, Knopp M et al. Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 17 (1998) (Abstract 1784).
   Google Scholar
• Novak A, Byrne M, Williamson R. Multicentre Phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br. J. Cancer 87, 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Solheim OP, Saeter G, Finnanger AM et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A Phase II study. Br. J. Cancer 65, 956–960 (1992).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Belani CP, Herndon II JE et al. Edatrexate with or without leucovorin rescue for malignant mesothelioma. Sequential Phase II trials by the Cancer and Leukaemia Group B. Cancer 86, 1985–1991 (1999).
   PubMed Web of Science ®Google Scholar
• Pinto C, Marino A, Guaraldi M et al. Combination chemotherapy with mitoxantrone, methotrexate and mitomycin (MMM regimen) in malignant pleural mesothelioma: a Phase II study. Am. J. Clin. Oncol. 24, 143–147 (2001).
   PubMed Web of Science ®Google Scholar
• Halme M, Knuutila A, Vehmas T et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br. J. Cancer 80, 1781–1785 (1999).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Weissman LB, Herndon JE II et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J. Clin. Oncol. 12, 1436–1442 (1994).
   PubMed Web of Science ®Google Scholar
• Baas P, Ardizzoni A, Grossi F et al. The activity of raltitrexed in malignant pleural mesothelioma: an EORTC Phase II study (08992). Eur. J. Cancer 39, 353–357 (2003).
   PubMed Web of Science ®Google Scholar
• Maisano R, Caristi N, Toscano G et al. Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study. Tumori 87, 391–393 (2001).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Doubre H, Le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. J. Clin. Oncol. 21(2), 349–354 (2003).
   PubMed Web of Science ®Google Scholar
• Van Meerbeck JP, Manegold C, Gaafar R et al. A randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma (MPM): an Intergroup study of the EORTC Lung Cancer Group and NCIC. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 7021).
   Google Scholar
• Adjei AA. Pemetrexed (Alimta®): a novel multitargeted antifolate agent. Expert Rev. Anticancer Ther. 3, 145–156 (2003).
   PubMedGoogle Scholar
• Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY-231514) in combination with cisplatin. J. Clin. Oncol. 17, 3009–3016 (1999).
   PubMed Web of Science ®Google Scholar
• Hughes A, Calvert P, Azzabi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20, 3533–3544 (2002).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21, 1556–1561 (2003).
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1, 545–553 (2002).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 14, 2636–2644 (2003).
   Google Scholar
• Paloetti P, Pistolese M, Rusthoven JJ et al. Correlation of pulmonary function tests with best tumor response status: results from the Phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 22, 659 (2003) (Abstract 2496).
   Google Scholar
• Liepa A, Rusthoven J, Denham C et al. Clinical benefit algorithm for malignant pleural mesothelioma: results from randomized trial of pemetrexed plus cisplatin versus cisplatin. Ann. Oncol. 13(Suppl. 5), 475 (2002).
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Hollen PJ, Liepa AM et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc. Am. Soc. Clin. Oncol. 22, 621 (2003) (Abstract 2496).
   Google Scholar
• Robinson BWS, Creaney J, Lake RA. Mesothelin family proteins and diagnosis of mesothelioma. Lancet 362, 1612–1616 (2003).
   PubMed Web of Science ®Google Scholar
• Jännen PA, Obasaju C, Simon G. A Phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). Proc. Am. Soc. Clin. Oncol. 626 (2002) (Abstract 7053).
   Web of Science ®Google Scholar
• Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193, 486–4875 (2001).
   Google Scholar
• Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lumphangiogenesis in human malignant mesothelioma tumors. Br. J. Cancer 81, 54–61 (1999).
   PubMed Web of Science ®Google Scholar
• Linder C, Linder S, Munch-Wikland E et al. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 18, 2063–2068 (1998).
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Abraham R, Harvie R et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized Phase II studies. Lung Cancer 41(Suppl. 2), 11 (2002) (Abstract O-26).
   Google Scholar
• Dazzi H, Hasleton PS, Thatcher N et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4 monoclonal antibody. Br. J. Cancer 61, 924–926 (1990).
   PubMed Web of Science ®Google Scholar
• Morocz IA, Schmitter D, Lauber B et al. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor α/epidermal growth factor receptor mitogenic pathway. Br. J. Cancer 70, 850–856 (1994).
   PubMed Web of Science ®Google Scholar
• Janne PA, Taffaro ML, Salgia R. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62, 5242–5247 (2002).
   PubMed Web of Science ®Google Scholar
• Garland L, Rankin C, Scott K et al. Molecular correlates of the EGFR signaling pathway in associations with SWOG S0218: a Phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-71881) in patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 22(14) (2004) (Abstract 3007).
   Google Scholar
• Govindan R, Kratzke RA, Herndon JE et al. Gefitinib in patients with malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B (CALGB 30101). Proc. Am. Soc. Clin. Oncol. 22, 630 (2003) (Abstract 2535).
   Google Scholar
• Giaccone G, O’Brien ME, Byrne MJ. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur. J. Cancer 38(Suppl. 8), 19–24 (2002).
   PubMed Web of Science ®Google Scholar
• Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin. Oncol. 26(2Suppl. 6), 3–10 (1999) (Abstract 2535).
   PubMed Web of Science ®Google Scholar